McGill University hospitals have participated in CALGB for the past 25 years. NCI funding for the past five years has permitted the establishment of an effective system of data collection throughout the five participating hospitals which is directed by the McGill Cancer Centre. This has coincided with increased activity at McGill in clinically directed research in neoplastic diseases. As the Group's activity shifted from passive contribution of protocol cases to participation in data evaluation and protocol generation some transient deterioration in case accrual occurred in 1986. This has been recognized and corrected. Accrual is now on target at an annualized rate of 140, due in part to the provision of adequate data collecting staff for the Queen Elizabeth and St. Mary's Hospitals during the past few months. McGill participating in the academic and administrative activities of CALGB has increased markedly over the past 5 years with representation on several core and on most of the administrative committees. We plan to extend our participation in the field of lymphoma and immunology. McGill has major immunology research projects in areas related to CALGB interest. Input into the planned bone marrow transplantation program will be significant as McGill is one of the leading marrow transplant centers in Canada and has had an active program during the past seven years in both autologous and allogeneic marrow transplantation. The many research projects under way at McGill in the oncology field provide a sound basis for increased scientific input into CALGB studies. These are detailed in the Institutional Profile.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mcgill University
Zip Code
H3 2T5
Dressler, Lynn G; Berry, Donald A; Broadwater, Gloria et al. (2005) Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 23:4287-97
Byrd, John C; Rai, Kanti; Peterson, Bercedis L et al. (2005) Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49-53
Peters, William P; Rosner, Gary L; Vredenburgh, James J et al. (2005) Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA J Clin Oncol 23:2191-200
Muss, Hyman B; Woolf, Susan; Berry, Donald et al. (2005) Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073-81
Peppercorn, Jeffrey; Herndon 2nd, James; Kornblith, Alice B et al. (2005) Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer 104:1580-9
Wetzler, Meir; Dodge, Richard K; Mrozek, Krzysztof et al. (2004) Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. Br J Haematol 124:275-88
Farag, Sherif S; Ruppert, Amy S; Mrozek, Krzysztof et al. (2004) Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study. Int J Oncol 25:143-51
Silver, Richard T; Peterson, Bercedis L; Szatrowski, Ted P et al. (2003) Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013. Leuk Lymphoma 44:39-48
Graziano, S L; Tatum, A; Herndon 2nd, J E et al. (2001) Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 33:115-23
Stone, R M; Berg, D T; George, S L et al. (2001) Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98:548-53

Showing the most recent 10 out of 22 publications